Latest Breaking News On - Conditional marketing authorizations - Page 2 : comparemela.com

European Commission Approves First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemc

- Over 8,000 patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia may be eligible for treatment -LONDON (BUSINESS WIRE) Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that the European Commission has granted conditional marketing authoriza.

United statesCity ofUnited kingdomFranco locatelliHeather nicholsReshma kewalramaniCompanies to workVertex pharmaceuticals incorporated nasdaqExchange commissionCatholic university of the sacred heartEuropean commissionDepartment of pediatric hematologyVertex pharmaceuticals incorporatedEuropean unionChief executive officerCatholic university

Vertex Pharmaceuticals Incorporated: Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

Vertex Pharmaceuticals Incorporated: Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia
finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesSaudi arabiaCity ofGreat britainManisha paiStefan klotterFranco locatelliHeather nicholsExchange commissionDepartment of pediatric hematologyVertex pharmaceuticals incorporatedEuropean commissionCompanies to workDrug authorityCommittee for medicinal products human use

Vertex Receives CHMP Positive Opinion for the First CRISPR/Cas9 Gene-Edited Therapy, CASGEVY™ (exagamglogene autotemcel), for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia

- If approved by the European Commission, patients 12 years of age and older with severe sickle cell disease or transfusion-dependent beta thalassemia, for whom hematopoietic stem cell.

United statesCity ofUnited kingdomSaudi arabiaGreat britainFranco locatelliEuropean unionExchange commissionCatholic university of the sacred heartCompanies to workCommittee for medicinal products human useEuropean medicines agencyDrug authorityVertex pharmaceuticals incorporated nasdaqDepartment of pediatric hematologyDrug administration

Form 10-K Nuvalent, Inc For: Dec 31

Form 10-K Nuvalent, Inc For: Dec 31
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

Boston collegeUnited statesUnited kingdomNew mexicoDuke universityNorth carolinaCollege of the holy crossNew hampshireNorthern irelandDana farber cancer instituteHarvard universityUniversity of massachusettsGreat britainAlexandra balcomJamesr porterDeborah miller

EU Authorizes Pfizer-BioNTech s COVID-19 Vaccine For Adolescents

NEW YORK CITY (dpa-AFX) - Pfizer Inc. (PFE) and BioNTech SE's (BNTX) COVID-19 vaccine has received the conditional marketing authorization in the European Union for use in adolescents 12 to 15

Pfizer incEuropean unionEuropean commissionEmergency use authorizationConditional marketing authorizationsஃபைசர் இன்க்ஐரோப்பிய தொழிற்சங்கம்ஐரோப்பிய தரகுஅவசரம் பயன்பாடு அங்கீகாரம்